March 17 (Reuters) - Drugmaker AstraZeneca (AZN.L) has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to $1 billion, it said on Monday, seeking to accelerate the development of ...

AstraZeneca saw 18% revenue growth in 2024, boosted by key drugs and global innovation. See here to know why we recommend a buy on AZN stock.

CNBC's Angelica Peebles and AstraZeneca CEO Pascal Soriot join 'Squawk Box' to discuss the company's breast cancer drug trial, the Trump administration's 'most favored nation' policy, R&D ...

CAMBRIDGE, England-- (BUSINESS WIRE)-- AstraZeneca today announces $3.5 billion of capital investment in the United States focused on expanding the Company’s research and manufacturing footprint ...

Astrazeneca unveiled an ambitious overhaul of its manufacturing and supply operations driven by deep tech, AI, and what it called a “self-healing” supply chain at London Tech Week. The firm ...

Trading in AstraZeneca 's (AZN -1.44%) American Depositary Shares (ADSes) was lively on Tuesday, on news that its leadership intends to directly list its sock on a U.S. exchange.

AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which would help the Anglo-Swedish drugmaker develop therapies for chronic ...

The multi-year deal focuses on building a multimodal AI-driven foundation model for oncology, using TempusAI’s de-identified oncology data. This partnership is a big win, matching Tempus AI’s ...

AstraZeneca today pledged $3.5 million to nonprofit organizations across the US as part of Accelerate Change Together (ACT) on Health Equity, an initiative t ...

Eli Lilly and AstraZeneca top a consultancy’s ranking of drug company R&D New assessment looks at progress in ‘innovation’ and ‘invention’ Adobe By Matthew Herper May 14, 2025 ...

Land of opportunity Since AstraZeneca has quite a presence in the U.S. healthcare market and does much of its business in the country, it makes abundant sense to shift the main stock market ...